MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

A presentation at The Liver Meeting® 2026 highlighted that metabolic dysfunction–associated steatotic liver disease (MASLD) significantly increases the risk of hepatocellular carcinoma (HCC) and other cancers. HCC risk is concentrated in patients with advanced fibrosis or cirrhosis, while extrahepatic cancer risk is broader. Clinicians are advised to screen for HCC selectively but ensure routine, age-appropriate cancer prevention for all patients with MASLD.
Why it matters
This research has significant implications for public health and clinical practice, as MASLD is highly prevalent globally and its link to various cancers necessitates updated screening and prevention strategies to improve patient outcomes.
At The Liver Meeting® 2026, Hashem B. El-Serag, MD, MPH, vice president of the Learning Health System and chair and professor of the Department of Medicine at Baylor College of Medicine in Houston, Texas, argued that metabolic dysfunction–associated steatotic liver disease (MASLD) changes cancer care in 2 ways. Hepatocellular carcinoma (HCC) risk is concentrated in patients with advanced fibrosis or cirrhosis, while the extrahepatic cancer burden is broader and not clearly fibrosis dependent.1 He concluded that clinicians should screen for HCC selectively but ensure routine, age-appropriate cancer prevention for all patients with MASLD.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in